Study of Nivolumab and Relatlimab in Advanced Mismatch Repair Deficient Cancers Resistant to Prior PD-(L)1 Inhibitor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Replimune Inc.
Fudan University
ImmunityBio, Inc.
7 Hills Pharma, LLC
Molecular Templates, Inc.
The Hospital for Sick Children
National Cancer Institute (NCI)